Spiderwort Biotechnologies Inc. Receives Health Canada Investigational Testing Authorization for Next-Generation Dermal Filler
® represents the next-generation in medical aesthetics leveraging Spiderwort Biotechnologies regenerative cellulose-based technology platform
OTTAWA, ON, June 10, 2025 /CNW/ - Spiderwort Biotechnologies Inc., a pioneering biotechnology company focused on cellulose-based regenerative medicine, today announced it has received Investigational Testing Authorization (ITA) from Health Canada for CelluJuve ®, its next-generation cellulose-based dermal filler currently under development.
The ITA enables Spiderwort Biotechnologies Inc. to initiate a human clinical trial in Canada to evaluate the safety and performance of CelluJuve ® for tissue augmentation and rejuvenation. The planned clinical trials will evaluate the interaction between CelluJuve® and human tissues. This authorization follows the company's successful completion of ISO 10993 biocompatibility testing and human skin safety testing for CelluJuve ®.
"Receiving the Investigational Testing Authorization from Health Canada is a critical inflection point in our mission to transform the landscape of regenerative medicine in multiple categories," said Dr. Charles M. Cuerrier, CEO of Spiderwort Biotechnologies Inc."This achievement validates our rigorous development approach and accelerates our path toward bringing CelluJuve ® to patients and clinicians who are seeking innovative alternatives in dermal fillers. We're excited to begin the clinical evaluation phase and demonstrate the potential benefits of our cellulose-based technology Aerocel™ in medical aesthetics and beyond."
"As a board certified dermatologist with extensive experience in facial aesthetics, I am encouraged by CelluJuve®'s innovative approach to tissue augmentation." Dr. Joely Kaufman, MD, FAAD, member of Spiderwort's Clinical Advisory Board, "The preliminary data suggests that this cellulose-based technology could potentially offer an alternative method to address the signs of facial aging. I look forward to seeing the clinical results of this promising biomaterial."
CelluJuve ® is under development to provide medical professionals with a cellulose-based alternative to current dermal fillers. The product is designed to work with the body to create a natural look and feel by providing a framework for collagen deposition, with the initial target for Spiderwort Biotechnologies Inc.'s research being nasolabial fold remediation.
The company's state-of-the-art ISO 5 cleanroom facility, announced earlier this year, will support the production of medical-grade CelluJuve ® for the upcoming trials, ensuring all materials meet the quality standards required for human use.
"CelluJuve® is a testament to where bold science can lead," said Dr. Andrew Pelling, Chief Science Officer at Spiderwort Biotechnologies Inc."We're demonstrating how plant-derived biomaterials can become a powerful foundation to address a variety of medical needs. These recent and critical regulatory advancements in our product portfolio reveal how nature inspired innovation can unlock entirely new frontiers in rejuvenating and regenerating human tissues."
CelluJuve ® is a device under development. While it has received Investigational Testing Authorization from Health Canada for clinical trials, it is not yet approved by Health Canada or the U.S. Food and Drug Administration (FDA) for commercial use, and it is not available for sale. The safety and effectiveness of CelluJuve ® in humans has not been fully established and will be evaluated in upcoming clinical trials.
For more information about Spiderwort Biotechnologies and CelluJuve ®, please visit https://spiderwortbio.com/product/cellujuve/.
About Spiderwort Biotechnologies Inc.
Spiderwort is transforming biotechnology with a platform of cellulose-based biomaterials that serve as the scaffolds for the regenerative medicine of the future. Spiderwort's biomaterials have shown promise in the treatment of spinal cord injuries and soft tissue regeneration. Spun out as a startup from the Pelling Lab, Spiderwort is led by CEO Charles M. Cuerrier and inspired by the work of CSO and TED Fellow Andrew E. Pelling. Learn more at spiderwortbio.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
14 hours ago
- Cision Canada
Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association's 85th Scientific Sessions
In a Phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once weekly treatment in patients with type 2 diabetes mellitus (T2DM), with significant HbA1c reductions alongside comprehensive benefits for body weight, blood pressure and blood lipid profiles. In a Phase 2b clinical trial, the bofanglutide injection showed superior HbA1c and body weight reduction than semaglutide (Ozempic ®) after 24 weeks of bi-weekly treatment in patients with T2DM, along with an acceptable safety and tolerability profile. In a Phase 2 clinical trial, the once-weekly insulin GZR4 injection demonstrated comparable efficacy and safety profiles in patients with T2DM after 16 weeks of treatment. Notably, GZR4 injection achieved superior HbA1c reduction in patients with inadequate glycemic control on prior basal insulin therapy compared to once-daily insulin degludec (Tresiba ®). BEIJING and BRIDGEWATER, N.J., June 21, 2025 /CNW/ -- Gan & Lee Pharmaceuticals (Gan & Lee, stock code: announced that the company presented multiple Phase 2 clinical study results of ultra-long-acting GLP-1 receptor agonist (GLP-1 RA) bofanglutide (research code: GZR18) injection and once-weekly basal insulin analog GZR4 injection during a poster presentation at the American Diabetes Association (ADA)'s 85th Scientific Sessions. Bofanglutide injection and GZR4 injection are investigational drugs that have not yet been launched in any country. Gan & Lee Pharmaceuticals does not recommend the use of any unapproved drugs/indications. Bofanglutide injection: A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 2a Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of Bofanglutide (GZR18) Injection in Chinese Patients with Type 2 Diabetes Mellitus (T2DM) In this Phase 2a clinical trial (NCT06256523), 36 adults with T2DM who had inadequate glycemic control through diet and exercise and/or irregular use of antidiabetic medications, were randomized to receive either bofanglutide injection (N=27) or placebo (N=9) once weekly (QW) for 23 weeks, with a dose escalating from 1.5 mg to 13 mg. The key efficacy endpoint was HbA1c change from baseline to week 23. After 23 weeks of treatment, the mean HbA1c change from baseline in the bofanglutide groups was -1.81% compared to 0.12% in the placebo group, with an estimated treatment difference of -1.93% points *. The proportion of participants achieving an HbA1c target of <7.0% and ≤6.5% was 57.7% and 46.2%, respectively, compared to zero in the placebo group. In terms of weight management, participants treated with bofanglutide experienced a mean reduction in body weight of 6.92 kg from baseline, corresponding to a 9.3% decrease, compared to a minimal reduction of 1.2% in the placebo group. Furthermore, bofanglutide showed comprehensive improvements over placebo in multiple metabolic parameters, including fasting plasma glucose (FPG), glycated albumin (GA), waist circumference (WC), blood pressure, and lipid profiles. In terms of safety, bofanglutide was well tolerated in patients with T2DM. Consistent with known GLP-1 RAs, the most common adverse events were gastrointestinal-related, primarily observed during the early dose-escalation period with mostly mild to moderate in severity. No hypoglycemic events or investigational product-related serious adverse events were reported during the study. Bofanglutide injection: A Multicenter, Randomized, Open-label, Active comparator-controlled Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of bofanglutide Injection versus Semaglutide (Ozempic ®) in Chinese Patients with T2DM In this Phase 2b clinical trial (NCT06256549), a total of 272 eligible Chinese patients with T2DM, who had inadequate glycemic control either after lifestyle intervention or despite stable use of oral antidiabetic drugs (OADs) for at least 3 months, were randomized to receive bi-weekly (Q2W) 12 mg (N=55), 18 mg (N=54), 24 mg (N=55) bofanglutide injections, or once-weekly (QW) 24 mg (N=54) bofanglutide injections, or 1 mg semaglutide (Ozempic ®, N=54) for 24 weeks of treatment, including the dose-escalation period. The primary endpoint was HbA1c change from baseline to week 24. After 24 weeks of treatment, the mean reductions in HbA1c from baseline were 1.87%, 2.28%, and 1.94% in the bofanglutide groups at 12 mg, 18 mg, and 24 mg Q2W, respectively, and -2.32% in the 24 mg QW group. All these treatment regimens showed greater HbA1c reductions compared to the semaglutide group (-1.60%), with the 18 mg Q2W and 24 mg QW bofanglutide groups demonstrating statistically significant superiority (p<0.001) *. Among drug-naïve patients with inadequate glycemic control despite lifestyle interventions, the 18 mg Q2W bofanglutide group achieved a mean HbA1c reduction of 2.98%, which was significantly greater than that observed with semaglutide (-2.04%; p<0.001)*. The proportions of patients achieving HbA1c target of <7.0% were 63.0% to 73.6% in the Q2W bofanglutide group, 75.0% in the QW bofanglutide group, and 70.0% in the semaglutide group. For the HbA1c ≤6.5% target, the corresponding proportions were 58.2% to 67.9%, 69.2%, and 62.0%, respectively. Furthermore, the mean change in body weight for all bofanglutide groups from baseline to week 24 ranged from -4.26 to -6.54 kg, compared to -3.25 kg in the semaglutide group *. Bofanglutide also greatly improved FPG, blood pressure, lipid profiles, and other metabolic parameters. In this study, bofanglutide was g enerally well tolerated, with safety and tolerability consistent with other known GLP-1 RAs. The most common adverse events were gastrointestinal-related, mostly mild to moderate in severity, and no sever e hypoglycemic events were observed. GZR4 injection: A Multicenter, Randomized, Open-label, Active-controlled, Treat-to-target Phase 2 Clinical Study Comparing the Efficacy and Safety of GZR4 Injection Versus Insulin degludec (IDeg, Tresiba ®) in Chinese patients with T2DM This Phase 2 clinical study (NCT06202079) enrolled a total of 83 Chinese patients with T2DM who had inadequate glycemic control on OADs (Part A), and 96 patients with inadequate control on OADs combined with basal insulin therapy (Part B). Participants were randomized to receive QW GZR4 injection (Part A: N=42; Part B: N=41) or once-daily IDeg (Tresiba ®) injection (Part A: N=48; Part B: N=48) for 16 weeks of treatment. The primary efficacy endpoint was the change in HbA1c from baseline to week 16. After 16 weeks of treatment, in patients from Part A, the mean change in HbA1c was comparable between GZR4 groups and IDeg groups (−1.50% versus -1.48%, p = 0.90). The proportion of participants achieving HbA1c target of <7.0% was 59.5% in the GZR4 group and 70.7% in the IDeg group, while the proportion achieving HbA1c target of ≤6.5% was 38.1% and 29.3%, respectively. In patients from Part B, GZR4 demonstrated significantly greater HbA1c reduction compared to IDeg (-1.26% vs -0.87%; p<0.01), with a higher proportion of patients achieving HbA1c targets of <7.0% and ≤6.5% (52.1% vs 29.2%; 25.0% vs 10.4%). In addition, improvements from baseline in FPG and time in range (TIR) were comparable between the GZR4 group and IDeg group. GZR4 achieved effective glycemic control without the need for a loading dose at the first administration, while the total weekly insulin dosage (mole) for GZR4 was approximately 40–50% of that for IDeg (p<0.001). In terms of safety, the incidence of adverse events was similar between the two groups. No severe hypoglycemic events or investigational product-related serious adverse events were reported during the study. * The clinical data were presented as mean (SE) value. The detailed results of the above Phase 2 clinical study will be published in a peer-reviewed journal. Conclusion and Future Direction The latest clinical results presented at this year's ADA conference highlight Gan & Lee Pharmaceuticals' leading position in the development of long-acting antidiabetic therapies. Building on these positive outcomes, the company will continue to advance the research and development of innovative treatments for diabetes. Currently, Gan & Lee has initiated and is accelerating large-scale Phase 3 clinical programs in China for bofanglutide injection and GZR4 injections for the treatment of type 2 diabetes, aiming to provide more effective treatment options for patients with diabetes. Forward-looking statements Forward-looking statements are based on our expectations and assumptions as of the date of the statements. Actual results may differ materially from those expressed in these forward-looking statements due to a variety of factors, and we can give no assurance that such results will be achieved in the future. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. About Gan & Lee Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin ®), fast-acting lispro injection (Prandilin™), fast-acting aspart injection (Rapilin ®), mixed protamine zinc lispro injection (25R) (Prandilin™25), aspart 30 injection (Rapilin ® 30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin ® 30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine ®). In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked first among all selected companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine ®) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee's competitiveness in both international and domestic markets. In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas.
Global News
a day ago
- Global News
Some Acuvue contact lenses are being recalled, Health Canada says
Health Canada says a voluntary recall has been issued by Johnson & Johnson Vision care over several models of one of its Acuvue contact lenses. A total of 13 models of the Acuvue Oasys Max 1-day Multi-Focal Contact Lenses are affected by the recall, with people advised to contact the manufacturer if more information is needed. The recall is due to a high density of microbubbles that could cause 'visual disturbances.' The microbubbles, also known as microscopic voids within the contact lens, were found in 'specific limited lots,' and Health Canada says while it poses no medical harm, it could cause visual disturbances, 'particularly in low-light conditions.' Get daily National news Get the day's top news, political, economic, and current affairs headlines, delivered to your inbox once a day. Sign up for daily National newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy Lenses with the lot or serial number of SENOFILCON A with a varying range of prescriptions are affected by the recall, with the full list available on Health Canada's website. Story continues below advertisement The recall began on June 12, however it does not advise how many affected products there might be nor a time frame for affected lenses. Health Canada posted about the recall on June 20.
Global News
a day ago
- Global News
Extreme heat can turn dangerous fast. Who is most vulnerable?
Doctors and health-care experts are warning Canadians to not only look after themselves but also check on others who could be vulnerable as large parts of central Canada face a sweltering heat wave. Global News chief meteorologist Anthony Farnell says a large heat ridge or dome will build over the Ohio Valley in the U.S. and expand into southeastern Canada by the end of the weekend. Temperatures are expected to reach the low to mid-30s C and the humidex could make that feel much higher, with humidex readings potentially into the mid-40s. When heat hits those levels, the body has to work harder to keep itself cool. 'The hypothalamus acts as the thermostat and sends signals to the heart to start beating faster, sends signals to our body to breathe a little faster and that helps the blood flow to the extremities so that we can dissipate heat through radiant heat loss,' said Dr. Samantha Green, a family physician at Unity Health Toronto with expertise in climate change and health. Story continues below advertisement 'It also sends signals so that we can cool down through evaporative cooling through sweating.' What does extreme heat do to your body? Prolonged exposure to heat can impact the human body in a variety of ways. One of the most common is heat exhaustion, which can lead to heat stroke. Heat exhaustion is characterized by headache, dizziness, extreme thirst, heavy sweating, muscle cramps and nausea and vomiting, according to Health Canada, and people are advised to immediately move to a cool place and drink water if experiencing these symptoms. If left untreated, that exhaustion can become heat stroke, which is defined by Johns Hopkins Medicine as the body being overwhelmed by excessive heat. Those suffering from heat stroke often have an internal temperature of 40 C or higher, warm, dry skin, confusion and nausea, and it can lead to worse conditions, including seizures, coma and even death. Story continues below advertisement While people will keep an eye on the temperature, studies show that people should also be aware of the 'wet bulb' temperature — when both humidity and air temperatures are high, it can be harder to shed heat and keep yourself cool. A 2010 study found that a wet-bulb temperature of 35 C that lasts longer than six hours could cause serious health impacts or even death. Get weekly health news Receive the latest medical news and health information delivered to you every Sunday. Sign up for weekly health newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy A study in the Journal of Applied Physiology in 2022 found that at 100 per cent humidity, the threshold could be as low as 31 C, while at 38 C, just 60 per cent humidity could be too much for the body. 4:47 Summer can be a dangerous time for our furry friends If you are suffering from heat stroke or you notice someone with similar symptoms, move to a cool place to rest and call 911, as it is a life-threatening medical emergency. Story continues below advertisement 'If you don't feel well from the heat, seek medical attention or call 911. Don't be afraid to ask for help,' said Caroline Metz, managing director of climate resilience and health at the Intact Centre on Climate Adaptation at the University of Waterloo. Vulnerable populations, such as youth and older adults or those with chronic conditions, may find it more difficult to beat the heat. Who's most at risk? Nemours Children's Health in the U.S. notes that children's bodies are still developing and may sweat at a lower rate than adults and start sweating at a higher temperature, putting them more at risk of heat-related illness. Older adults face higher risks as they may have trouble accessing cool spaces due to mobility or transportation challenges, and those living alone may be more vulnerable as a result, according to B.C. Interior Health. Story continues below advertisement Older adults, as well as other Canadians, may also have chronic underlying health conditions or be taking medication that could interfere with the body's ability to stay cool. The U.S. Centers for Disease Control and Prevention notes that those with these conditions may be less likely to respond to changes in temperature, and that those with heart disease, mental illness and obesity have a higher risk of heat-related illness. 4:08 Summer heat can be dangerous for seniors 'It's also why people with chronic health conditions are more at risk of developing heat exhaustion, heat stroke, where the body's natural cooling mechanisms break down and the core body temperature exceeds 40 degrees,' Green said. 'That's where we end up with massive inflammation and failure of organs in the body.' People taking chronic medications can also be affected. Green said beta blockers, for example, prevent the heart from beating faster in response to heat and keep the body from naturally being able to cool down. Story continues below advertisement It's not just health conditions or age that can pose vulnerabilities, however. 'Anybody who's working outside or people experiencing homelessness, they're more exposed to heat and that's a group or a population that's more at risk,' Metz said. How to protect yourself and others Metz notes that during heat waves, it's important for people to watch out for others and check in on neighbours because those living alone or socially isolated can also be vulnerable to heat. A B.C. coroner's report following the 2023 heat dome noted that 98 per cent of the 619 deaths identified as being related to heat occurred indoors, with 56 per cent of those who died living alone. 'Social cohesion or social connectedness has been shown to be a very important factor for resilience and for health during heat waves,' Metz said. Story continues below advertisement 'In fact, in some cultures where there are multi-generational families living together, it's just very natural for people to care about others … so they don't often experience the same kind of situation that we might have here in North America, where we have one generation living in a household. 'The ability to reach out, call someone, or stop by has been shown to greatly support health and well-being for people who are isolated.' She added that older adults and those living alone should reach out to other people to let them know they're on their own and are open to having someone check on them during periods of extreme weather. As a heat wave enters Ontario later this weekend, Metz said people should stay in the coolest part of their home if possible or go to a community cooling centre, wear lighter-coloured clothing if you have to go out, keep your doors and windows closed during the hottest parts of the day, and turn off items that may produce extra heat in your home. 'If you need to be out, you want to do that during the parts of the day that are the coolest,' she suggested, noting this means early mornings and late evenings.
